Mobile

A 12-Week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Study of Two Doses of VX-702 in Subjects with Moderate to Severe Rheumatoid Arthritis

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-000549-13

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

- To define the clinical response to placebo and two doses of VX-702 in subjects with RA using the number of 20% responses as defined by the American College of Rheumatology (ACR20) at Week 12 by applying the Jonckheere-Terpstra trend analysis - To evaluate the safety and tolerability of 2 dose levels of VX-702 compared to placebo, when administered for 12 weeks to subjects with RA

Critère d'inclusion

  • Rheumatoid Arthritis

Liens